Legacy AI grade · Sources dated 2026-07-25. Not expert reviewed. Coverage is limited to the listed sources. About the new summary workflow
Calcium Alpha-Ketoglutarate for Aging
Verdict: Insufficient Evidence
Across 6 PubMed studies, the evidence for Calcium Alpha-Ketoglutarate in Aging grades Tier U — unverified / insufficient. Research is still too limited to draw a firm conclusion.
U ⚫ U Unverified Insufficient Evidence
Why this grade7-layer evidence engine
⚖️
Scoring transparency
All scores computed by a 7-layer evidence engine — fully auditableRaw score 0.45
D
C
B
A
S
← counter-evidence / ineffectiveeffective / strong evidence →
Final grade
U · Insufficient Evidence
Confidence
55%
Conflicting evidence
Evidence level
E7
Single small RCT
▸View the full decision path (audit trail)
- compute_raw_score — 加權公式: L2×0.30 + L3×0.25 + L5×0.25 + L11×0.10 + L1×0.10 = 0.453
- tier_from_score — 依分數區間映射至 tier letter
- apply_hec_rules — 無高階證據可裁決
- tier_strict_requirement_check — Tier 條件達標，未降階
- detect_disputes — 偵測到 0 個 hard + 0 個 soft dispute
- decide_status — 依 tier + dispute 結果決定 status
PubMed studies (6)L2 · primary research & systematic reviews
Rejuvant®, a potential life-extending compound formulation with alpha-ketoglutarate and vitamins, conferred an average 8 year reduction in biological aging, after an average of 7 months of use, in the TruAge DNA methylation test
Finding: Average decrease in biological (DNA methylation) age of ~8 years after ~7 months (p=6.538x10^-12). NO placebo/control group, NO randomization; participants self-selected Rejuvant users. Methodologically weak; commercial relationship (authors affiliated with the product).
View on PubMed Alpha-ketoglutarate supplementation and BiologicaL agE in middle-aged adults (ABLE)-intervention study protocol
Finding: STUDY PROTOCOL ONLY — describes the first randomized, double-blind, placebo-controlled trial of Ca-AKG for biological age. As of 2026-05 NO outcome results have been published. This is the trial that would, if positive, provide the first controlled human efficacy evidence.
View on PubMed Alpha-Ketoglutarate, an Endogenous Metabolite, Extends Lifespan and Compresses Morbidity in Aging Mice
Finding: In females, Ca-AKG significantly increased median (+16.6%) and 90th-percentile maximal (+19.7%) lifespan; in males numerically greater (+9.6%/+12.8%) but NS. Reduced frailty index and systemic inflammatory cytokines; proposed IL-10 induction suppressing chronic inflammation -> compression of morbidity. ANIMAL evidence only.
View on PubMed The metabolite alpha-ketoglutarate extends lifespan by inhibiting the ATP synthase and TOR
Finding: alpha-KG prolonged C. elegans lifespan by ~50% and delayed age-related decline; mechanism via inhibition of ATP synthase (subunit beta) and TOR, partly mediating dietary-restriction longevity. Foundational mechanistic paper. INVERTEBRATE evidence only.
View on PubMed Alpha-ketoglutarate extends Drosophila lifespan by inhibiting mTOR and activating AMPK
Finding: AKG extended Drosophila lifespan via mTOR inhibition and AMPK activation, consistent with caloric-restriction mimetic mechanism. INVERTEBRATE evidence only.
View on PubMed Pleiotropic effects of alpha-ketoglutarate as a potential anti-ageing agent
Finding: Review summarising AKG's roles in energy metabolism, epigenetic regulation (TET/JmjC dioxygenase cofactor), collagen synthesis, immune modulation and potential anti-ageing effects; emphasises that most evidence is from model organisms and that robust human RCT data are lacking.
View on PubMed Regulatory & authoritative positionsL4/L5 · FDA / EMA / NIH ODS / Cochrane / Mayo …
L4a US FDA
Cautious
calcium alpha-ketoglutarate is legal in the U.S. as a supplement ingredient under the Dietary Supplement Health and Education Act (DSHEA), provided manufacturers follow GMP standards and avoid unverified therapeutic claims source↗
L4b EU EFSA
Neutral
EFSA has not granted specific authorization for novel food use of calcium alpha-ketoglutarate source↗
L4d TW TFDA / 衛福部
Cautious
可供食品使用原料彙整一覽表 source↗